Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.21.2
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Statement [Abstract]        
Sales, net of returns and allowances $ (576,602) $ 564,707 $ 1,147,334 $ 740,949
Cost of sales 11,549,187 2,815,242 32,570,616 6,074,577
Gross loss (12,125,789) (2,250,535) (31,423,282) (5,333,628)
Operating expenses        
Selling, general and administrative 10,579,586 5,950,058 24,470,953 15,464,926
Research and development 2,801,394 1,614,485 8,788,969 5,133,325
Total operating expenses 13,380,980 7,564,543 33,259,922 20,598,251
Loss from operations (25,506,769) (9,815,078) (64,683,204) (25,931,879)
Interest (income) expense, net (18,599,130) 74,315,644 (23,040,886) 185,638,961
Other loss (income) 77,127,266 0 225,432,884 (864,900)
Loss before benefit for income taxes (84,034,905) (84,130,722) (267,075,202) (210,705,940)
Benefit for income taxes (2,919,491) 0 (21,833,930) 0
Net loss $ (81,115,414) $ (84,130,722) $ (245,241,272) $ (210,705,940)
Net loss per share of common stock        
Basic (in usd per share) $ (0.66) $ (0.78) $ (1.99) $ (2.52)
Diluted (in usd per share) $ (0.77) $ (0.78) $ (2.07) $ (2.52)
Weighted average shares used in computing net loss per share of common stock        
Basic (in shares) 123,584,023 107,406,000 123,186,350 83,611,526
Diluted (in shares) 129,251,351 107,406,000 128,853,678 83,611,526